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The recent identification of nonprimate hepaciviruses in dogs and then in horses prompted us to look for pegiviruses (GB virus-
like viruses) in these species. Although none were detected in canines, we found widespread natural infection of horses by a novel
pegivirus. Unique genomic features and phylogenetic analyses confirmed that the tentatively named equine pegivirus (EPgV)
represents a novel species within the Pegivirus genus. We also determined that EPgV causes persistent viremia whereas its clini-
cal significance is undetermined.
Hepatitis C virus (HCV) and human pegiviruses (HPgV) infectan estimated 2 and 5% of the world’s population, respec-
tively. HCV, HPgV (formerly referred to as GB virus C or hepatitis
G virus), and other genetically related viruses belong to two closely
related genera of the family Flaviviridae, named Hepacivirus and
Pegivirus (1). HCV is hepatotropic, and infection of humans can
trigger liver damage characterized by fibrosis, cirrhosis, and hep-
atocellular carcinoma (2). HPgV is lymphotropic (3), but its
pathogenicity in humans is unknown. Among people with other
blood-borne or sexually transmitted infections, HPgV is more
prevalent. Up to 40% of HIV-infected individuals have HPgV
viremia (1, 4, 5). The viruses genetically most similar to human
HCV include GB virus B (GBV-B) and the recently discovered
nonprimate hepacivirus (NPHV) (6). The natural host of NPHV
is the horse (6, 7), while GBV-B’s origin and natural host remain
elusive. The viruses genetically most similar to HPgV include sim-
ian (GBV-A) and bat (GBV-D) pegiviruses (SPgV and BPgV, re-
spectively) (1, 8, 9). The recent identification of NPHV in horses
(7) prompted us to look for the presence of pegivirus-like virus
infections in dogs and horses. Here we report the identification,
complete genome sequence, and initial characterization of a pegi-
virus that infects horses.
Identification, complete genome, and polyprotein of equine
pegivirus (EPgV). Degenerate primers targeting the conserved
helicase motifs of known pegivirus species were used to screen
serum samples from 12 horses with elevated liver enzyme levels.
The degenerate PCR assay used primers AK4340F1 (5=-GTACTT
GCTACTGCNACNCC-3=) and AK4630R1 (5=-TACCCTGTCAT
AAGGGCRTC-3=) for the first round of PCR. Primers AK4340F2
(5=-CTTGCTACTGCNACNCCWCC-3=) and AK4630R2 (5=-TA
CCCTGTCATAAGGGCRTCNGT-3=) were used for the second
round. For the first round, the PCR cycle included 8 min of dena-
turation at 95°C; 10 cycles of 95°C for 40 s, 60°C for 1 min, and
72°C for 40 s; 30 cycles of 95°C for 30 s, 56°C for 45 s, and 72°C for
40 s; and a final extension at 72°C for 10 min. For the second
round, the PCR cycle included 8 min of denaturation at 95°C; 10
cycles of 95°C for 40 s, 64°C for 1 min, and 72°C for 40 s; 30 cycles
of 95°C for 30 s, 58°C for 45 s, and 72°C for 40 s; and a final
extension at 72°C for 10 min. All PCR products approximately 300
bp in length were sequenced to confirm the results.
Two samples were PCR positive, and amplicon sequencing re-
vealed viral sequences highly divergent from all known pegivi-
ruses. Unbiased high-throughput sequencing using the Ion Tor-
rent Personal Genome Machine was done to acquire more
sequences of the novel virus. A complete genome was acquired by
primer walking, gap-filling PCRs, 5= random amplification of
cDNA ends (RACE), and 3= poly(A/G/U) tailing (6, 7). The com-
plete genome sequence of the new virus (isolate C35) contains
11,197 nucleotides (nt) and is the longest genome of any known
Hepacivirus or Pegivirus described to date. Following the use of
host names to describe pegiviruses (1), we have therefore tenta-
tively named this EPgV. Deduced translation of the EPgV genome
indicated the presence of three possible initiation codons at nt
499, 592, and 616. However, the presence of a polypyrimidine
tract (PPT) at nt 573 to 589, of single nucleotide insertions/dele-
tions at nt 570 and 581 in different EPgV isolates, and of a stable
stem-loop formed by nt 589 to 607 indicated that the AUG codon
at position 616 is most likely to be the initiation codon. Assuming
this initiation site, the EPgV genome includes a 5= untranslated
region (UTR) of 615 nt, a single open reading frame (ORF) en-
coding a putative polyprotein 3,305 amino acid (aa) residues in
length, and a 3= UTR of up to 664 nt. Comparative genetic analysis
indicated that the EPgV polyprotein contains three structural (E1,
E2, X) and six nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and
NS5B) proteins (Fig. 1A). In common with a previous analysis of
BPgV (8), the EPgV polyprotein sequence shows additional pre-
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dicted signalase sites at positions 13 and 498 (Fig. 1C). The first
represents a signal peptide for the translocation of E1 on the en-
doplasmic reticulum membrane. The second, in conjunction with
the downstream signalase site at the start of NS2 (position 734),
creates a potential, moderately glycosylated potential homolog of
the X protein reported in BPgV. The NS3 protein of EPgV con-
tains a sequence motif for serine proteases (histidine 57, aspartic
acid 81, serine 139) in the N-terminal portion and for nucleoside
triphosphatase and RNA helicase (GSGKS at positions 208 to 212)
in the C-terminal portion. The NS5B protein of EPgV is 596 aa
long and contains functional RNA-dependent RNA polymerase
motifs in palm, fingers, and thumb subdomains. The palm region
contains five different motifs, A to E, that play a major role in the
polymerization ability of viral polymerase. EPgV motif A contains
the D-X4-D region (DATCFD), motif B contains Gx3TTx4N
(GVYTTSSAN), and motif C contains the highly conserved GDD
active site (HGDD) (10).
Sequence relationships with known viruses. To assess the re-
latedness of EPgV to other pegiviruses, their coding sequences
were aligned and pairwise distances between structural and non-
structural genome regions were computed (Table 1). Proteins
were aligned by using MUSCLE with default settings in the
SSE sequence editor (11–13) (http://www.virus-evolution.org
/Software). EPgV was substantially divergent from all other se-
quences, with amino acid divergences ranging from 62 to 77% in
structural genes (E1, E2, and X) and from 49 to 59% in the non-
structural region. The 5= UTR showed short regions of homology
to HPgV and SPgV, while the 3= UTRs matched no other pegivirus
or other sequences found in GenBank by BLAST searching. With
a scanning window of 67 aa, the sequence divergence between
EPgV and other pegiviruses was analyzed across the genome (Fig.
1B). By comparison of BPgV and primate pegivirus (4), the most
conserved regions within the Pegivirus genus were the NS3 and
NS5B genes, with high sequence divergence in the E1 and E2 gly-
coproteins and NS4B and no homology to other sequences in
GenBank in extended regions of NS4A and NS5A.
FIG 1 (A) Amino acid sequence divergence between EPgV and HPgV, SPgV, and BPgV based on 201-nt fragments in 6-nt increments across the genome
alignment (midpoint plotted on the y axis). Within-species distances for HPgV and SPgV are included for comparison. The divergence scan commenced at the
predicted signalase cleavage site at the start of the E1-encoding genes. (B, C) Genome diagram of EPgV showing predicted N-linked glycosylation sites (Nx[S/T];
vertical arrows) and proposed cleavage sites (sequence positions were numbered on the basis of the EPgV sequence). Cleavage sites in the EPgV polyprotein and in
other pegiviruses were predicted by alignment and homology to sites previously identified in SPgV (sites NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B) and
by comparison with predicted signalase sites between structural proteins and the NS2/NS3 cleavage site of BPgV. Potential signalase sites in EPgV were evaluated by using
the SignalP 4.1 server, which identified homologous cleavage sites that aligned with those in BPgV, including the boundaries of the novel proposed X protein.
Kapoor et al.
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Sequence comparisons were extended to include homologous
sequences from the Hepacivirus genus identified in the NS3 and
NS5B regions that could be aligned (Fig. 2). Bootstrapped maxi-
mum-likelihood trees of the NS3 and NS5B regions of pegivirus
and homologous regions of HCV and other hepaciviruses were
generated by using RAxML with the PROTGAMMA model
(gamma distribution for rates over sites, Dayhoff amino acid sim-
ilarity matrix with all model parameters estimated by RAxML)
and 100 bootstraps (14). Phylogenetic trees of the two genome
regions were topologically equivalent, although with some differ-
ences in relative branch length. The analysis confirmed the sepa-
rate grouping of EPgV from all other pegiviruses (Fig. 2).
RNA secondary structure in the UTRs and coding regions of
the EPgV genome. The 5= UTR of EPgV is predicted to be 615 nt
long, similar in length to those of other pegiviruses. To improve
the accuracy of RNA structure predictions, complete or partial 5=
UTR sequences from 18 other infected horses in addition to C35
were included in the analysis. Structure prediction used PFOLD, a
stochastic context-free grammar method, to identify phylogeneti-
TABLE 1 Nucleotide and translated amino acid sequence divergences of
structural and nonstructural genes of EPgV and other pegiviruses
Gene category and virus
% Divergence
EPgV HPgV SPgV BPgV
Structural (E1, E2, X)
EPgV 59.2a 63.0a 62.8a
HPgV 69.7b 52.2a 54.2a
SPgV 76.6b 61.8b 56.4a
BPgV 77.3b 62.6b 67.0b
Nonstructural (NS2-NS5B)
EPgV 51.7a 52.3a 50.4a
HPgV 57.7b 46.4a 50.9a
SPgV 59.1b 48.8b 51.4a
BPgV 56.3b 56.1b 57.6b
a Nucleotide level.
b Amino acid level.
FIG 2 Maximum-likelihood trees of amino acid sequences from the NS3 (nt 3545 to 5523 in the C35 EPgV genome) and NS5B (nt 8743 to 10231) regions of
EPgV and other pegiviruses. Pegiviruses were compared with homologous regions of hepaciviruses (HCV genotypes 1a to 7a, NPHV, and GBV-B). Sequences
used in phylogenetic analysis: SPgV and GBV-Ccpz, HGU22303, AF023424, AF023425, HGU94421, GVU84961, and AF070476; HPgV (all complete genomes
showing2% divergence from each other), AB008342, D87709, D87711, AB003290, D87714, D90601, D87712, D87708, D87715, D87263, D87262, AB003293,
AB003288, D87710, D87713, HGU94695, HGU75356, AF006500, AB013501, HGU63715, AF309966, AF121950, AF031827, AB003289, AY196904, D87255,
HGU44402, AF104403, D90600, HGU45966, AY949771, AB008336, AB003291, HGU36380, AB013500, AB021287, AB018667, AB003292, HQ331234,
HQ331235, HQ331233, AB010193, AF017560, AB008335, AF081782, AF031828, and AF031829; BPgV, GU566735 and GU566734.
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FIG 3 (A) Preliminary RNA secondary structure of the EPgV 5= UTR based on consensus predictions from PFLOD, STRUCTUREDIST, and ALIFOLD.
IRES-associated sequences (GNRA motif and PPT) are labeled. Bases polymorphic between different variants of EPgV are shown in boxes and color coded
according to their effects on base pairing (see key). IC, initiation codon. (B) Schematic of elements in the 3= UTR and prediction of strong stem-loop structures.
The repeat sequence region is drawn in blue, the conserved sequence region is in black, and the RSE (CTAACTCTNCGTGAGAT) is in red. A different RSE found
in the conserved region is in orange (B1, B2). Strong stem-loop structures are indicated with horizontal lines and numbered with roman numerals in the repeat
sequence region (the first stem-loop is given a zero since it does not have the RSE), with letters in the first part of the conserved region, and with numbers at the
genome terminus. Additional structures in the conserved sequence could not be accurately determined because of a lack of variation among the isolates analyzed
and a lack of homologous sequences in other viruses. Sequence alignments of isolates C35, D15, 8211574, and G48 are indicated at the bottom, with dotted lines
representing internal deletions.
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cally conserved covariant sites supporting an RNA structure
model (15), STRUCTUREDIST in the SSE package, which iden-
tifies conserved paired and unpaired bases in minimum-energy
folds (16); and a combined minimum-energy/covariant site de-
tection method implemented in ALIFOLD (16). Secondary-struc-
ture predictions were moderately consistent among all three
methods, although PFOLD predicted no consistent structure of
the 5= UTR beyond position 290 and ALIFOLD between the start
and position 200 and between 520 and the end of the 5= UTR.
Combining predictions, however, allowed a preliminary consen-
sus structure model to be generated (Fig. 3A). It should be noted
that none of the structure prediction methods can predict tertiary-
structure elements, such as pseudoknots, that are present in some
viral 5= UTR structures. Furthermore, predictions could not be
guided by comparison with other pegiviruses, as the regions of
homology were highly restricted, and the HPgV and SPgV pre-
dicted structures differed from each other and from that of EPgV
(17).
The consensus structure of the EPgV 5= UTR comprised two
large stem-loops (labeled D and G), several possible smaller ones
(A, B, C, J, and K) positioned 5= and 3= to them, and an interme-
diate stem-loop, F. These structures are larger than, although po-
sitioned similarly to, stem-loops II and IV described in HPgV and
SPgV (17), whereas stem-loop H is positioned similarly to SL-IVB.
Comparative sequence data from different variants of EPgV were
strongly supportive of the model, with most variable sites and
insertions/deletions occurring in predicted unpaired regions
(shaded green) and with two exceptions, variable sites in paired
regions showing covariant or semicovariant compensatory substi-
tutions to maintain pairing (shaded red and pink). Several fea-
tures of the 3=-terminal half of the EPgV 5= UTR are consistent
with an internal ribosome entry site (IRES) structure. It contains a
predicted unpaired PPT between positions 574 and 590. Addi-
tionally, stem-loop H positioned upstream contains a terminal
GNRA tetraloop found in most virus IRES structures. Indeed, the
arrangement of stem-loops G and H, followed by the PPT, a cryp-
tic base-paired start codon in stem-loop K, an additional unpaired
region, and finally the likely authentic start codon, is remarkably
similar to the structure of type I IRESs of enteroviruses (in the
virus familyPicornaviridae). Nonetheless, physical mapping of the
5= UTR and functional characterization are required to confirm
this putative structural homology.
Analysis of the 3= UTRs from four different isolates revealed a
5= 162- to 284-nt repeat element region, including three to six
repeat sequence elements (RSEs), followed by a highly conserved
380-nt sequence. The conserved region contained additional but
different RSEs. The RSEs in the 5= region were predicted to fold
into conserved stem-loop structures (Fig. 3B). The existence of
multiple repeat elements and their incorporation into a repetitive
array of stem-loops have not been described in other mammalian
viruses previously, and their functional role remains to be deter-
mined. Notably, 3= UTR sequences from other pegiviruses show
no sequence homology with the EPgV 3= UTR or comparable
repeated elements.
Thermodynamic folding analysis of the EPgV genome revealed
a 10.7% free-energy difference between its minimum folding en-
ergy and that of sequence order-randomized controls (MFED), an
observation consistent with the presence of genome scale or-
dered RNA structure in the EPgV genome (7). This MFED was
similar to those of HPgV (mean, 12.8% [range, 11.7 to 13.3%]),
SPgV (mean, 13.3% [range, 12.7 to 13.8%]), and BPgV (9.7 and
10.7%) (6).
Prevalence and persistence of EPgV. To estimate the preva-
lence of EPgV, we studied two sets of available serum/plasma sam-
ples collected in the United States by reverse transcription (RT)-
PCR with conserved primers in NS3. For the one U.S. sample set,
the viremia frequencies were 3/12 (25%) among horses with ele-
vated liver enzymes and 4/62 (6.4%) among healthy animals (P
0.08 by Fisher’s exact test). In an Alabama herd of healthy horses
that were tested at three time points between 2008 and 2012, 6/19
(32%), 6/29 (21%), and 4/27 (15%) were positive. Two of these
horses remained infected over a period of at least 3.5 years,
whereas four animals apparently cleared the infection and new
infections were observed in other animals. Though our study was
not designed to draw conclusions about tissue tropism, EPgV se-
quences were detected in liver and lymph node biopsy samples, as
well as in peripheral blood mononuclear cells, from the two
chronically infected Alabama horses. Semiquantitative PCR did
not reveal major quantitative differences in the presence of EPgV
RNA between these tissues. Using quantitative RT-PCR, the viral
RNA concentration in serum was determined to range from 104.5
to 106.5 genome equivalents per ml. Viral RNA was not detected in
tracheal wash samples from these animals. Among the liver au-
topsy samples from nine horses (in California) with a range of
causes of death, one sample was positive (from a horse that died of
emaciation and a collapsed trachea).
Conclusions. The recently designated genus Pegivirus of the
family Flaviviridae currently includes three virus species that in-
fect humans, primates, and bats. Recently, we identified hepacivi-
ruses in horses (NPHV) that represent the closest known animal
homolog of HCV (7). In the present study, we report the identifi-
cation of the first pegivirus that infects horses. While our paper
was in revision, a new Pegivirus species, named Theiler’s disease-
associated virus (TDAV), was identified in horses (18). Our se-
quence analysis confirmed that EPgV and TDAV are two geneti-
cally distinct Pegivirus species. These studies suggest that both
hepaciviruses and pegiviruses may be widely distributed among
different mammalian species. Our study and available samples
were not sufficient to determine the health relevance of EPgV
infection in horses; however, the limited biopsy data suggest that
this virus may not be strictly hepatotropic. The complete genome
sequence of EPgV will enable studies of EPgV sequence diversity
and the development of effective diagnostic reagents to conduct
studies of transmission, tissue tropism, and disease association.
Nucleotide sequence accession number. The nucleotide se-
quence of the new virus (isolate C35) has been submitted to
GenBank and assigned accession no. KC410872.
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